DOI QR코드

DOI QR Code

Association between the MDM2 T309G Polymorphism and Leukemia Risk: a Meta-analysis

  • Yan, Yu-Lan (Department of Clinical Laboratory, Affiliated Hospital of Hainan Medical College) ;
  • Han, Feng (Department of Clinical Laboratory, Affiliated Hospital of Hainan Medical College) ;
  • Tan, Wen-Min (Department of Clinical Laboratory, Affiliated Hospital of Hainan Medical College) ;
  • Wu, Cui-Ping (Department of Clinical Laboratory, Affiliated Hospital of Hainan Medical College) ;
  • Qin, Xi (Department of Clinical Laboratory, Affiliated Hospital of Hainan Medical College)
  • Published : 2014.08.30

Abstract

Several studies have suggested associations between MDM2 (mouse double minute 2 homolog) polymorphisms and leukemia risk, but they reported contradictory results. For better understanding of the effect of MDM2 T309G polymorphism on leukemia risk, we performed a meta-analysis. All eligible studies were identified through a search of PubMed, Web of Science, EMBASE, and Chinese Biomedical Literature (CBM) databases before May 2014. Assessment of associations between the MDM2 T309G polymorphism and leukemia risk was conducted by odds ratios (ORs) and 95% confidence intervals (95% CIs). Finally, a total of 11 publications covering 12 case-control studies with 2, 362 cases and 5, 562 controls concerning MDM2 T309G polymorphism with respect to leukemia were included in the meta-analysis. Significant associations were found between MDM2 T309G polymorphism and leukemia risk in four models in overall populations (G vs T: OR=1.29, 95% CI=1.11-1.49, p=0.001; GG vs TT: OR=1.67, 95% CI=1.21-2.30, p=0.002; GG vs TG/TT: OR=1.56, 95% CI=1.21-2.00, p=0.001; GG/TG vs TT: OR=1.28, 95% CI=1.05-1.57, p=0.015). In the sub-group analysis according to ethnicity, increased leukemia risks were observed in three genetic models among Asians but not Caucasians. In conclusion, the results of our meta-analysis suggest that the MDM2 T309G polymorphism can increase the risk of leukemia, especially among Asian populations.

Keywords

MDM2;polymorphism;leukemia;meta-analysis

References

  1. Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101. https://doi.org/10.2307/2533446
  2. Bjork J, Johansson B, Broberg K, Albin M (2009). Smoking as a risk factor for myelodysplastic syndromes and acute myeloid leukemia and its relation to cytogenetic findings: a case-control study. Leuk Res, 33, 788-91. https://doi.org/10.1016/j.leukres.2008.10.009
  3. Bond GL, Hu W, Bond EE, et al (2004). A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell, 119, 591-602. https://doi.org/10.1016/j.cell.2004.11.022
  4. Chen J, Zhu B, Li Y (2013). Genetic variations in MDM2 and P53 genes confer risk for adult acute lymphoblastic leukemia in a Chinese population. DNA Cell Biol, 32, 414-9. https://doi.org/10.1089/dna.2012.1900
  5. Chen QW, Chen H, Cheng JS, Meng ZQ (2014). MDM2 SNP309T>G polymorphism and hepatocellular carcinoma risk: a meta-analysis. Tumour Biol, 35, 4147-51. https://doi.org/10.1007/s13277-013-1543-z
  6. Chen W, Wu Q, Ren H (2014). Meta-analysis of associations between MDM2 SNP309 polymorphism and gastric cancer risk. Biomed Rep, 2, 105-11.
  7. Chen YL, Chang YS, Chang JG, Wu SM (2009). Genotyping of single nucleotide polymorphism in MDM2 genes by universal fluorescence primer PCR and capillary electrophoresis. Anal Bioanal Chem, 394, 1291-7. https://doi.org/10.1007/s00216-008-2416-y
  8. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. https://doi.org/10.1016/0197-2456(86)90046-2
  9. Do TN, Ucisik-Akkaya E, Davis CF, Morrison BA, Dorak MT (2009). TP53 R72P and MDM2 SNP309 polymorphisms in modification of childhood acute lymphoblastic leukemia susceptibility. Cancer Genet Cytogenet, 195, 31-6. https://doi.org/10.1016/j.cancergencyto.2009.05.009
  10. Dong HJ, Fang C, Fan L, et al (2012). MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL. Int J Cancer, 130, 2054-61. https://doi.org/10.1002/ijc.26222
  11. Ebid GT, Sedhom IA, El-Gammal MM, Moneer MM (2012). MDM2 T309G has a synergistic effect with P21 ser31arg single nucleotide polymorphisms on the risk of acute myeloid leukemia. Asian Pac J Cancer Prev, 13, 4315-20. https://doi.org/10.7314/APJCP.2012.13.9.4315
  12. Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34. https://doi.org/10.1136/bmj.315.7109.629
  13. Ellis NA, Huo D, Yildiz O, et al (2008). MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood, 112, 741-9. https://doi.org/10.1182/blood-2007-11-126508
  14. Estey EH (2001). Prognostic factors in acute myelogenous leukemia. Leukemia, 15, 670-2.
  15. Finch SC (2007). Radiation-induced leukemia: lessons from history. Best Pract Res Clin Haematol, 20, 109-18. https://doi.org/10.1016/j.beha.2006.10.009
  16. Gamazon ER, Lamba JK, Pounds S, et al (2013). Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients. Blood, 121, 4366-76. https://doi.org/10.1182/blood-2012-10-464149
  17. Gao J, Kang AJ, Lin S, et al (2014). Association between MDM2 rs 2279744 polymorphism and breast cancer susceptibility: a meta-analysis based on 9, 788 cases and 11, 195 controls. Ther Clin Risk Manag, 10, 269-77.
  18. Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58. https://doi.org/10.1002/sim.1186
  19. Jiang D, Hong Q, Shen Y, et al (2014). The diagnostic value of DNA methylation in leukemia: a systematic review and metaanalysis. PLoS One, 9, e96822. https://doi.org/10.1371/journal.pone.0096822
  20. Lichtman MA (2010). Obesity and the risk for a hematological malignancy: leukemia, lymphoma, or myeloma. Oncologist, 15, 1083-101. https://doi.org/10.1634/theoncologist.2010-0206
  21. Liu J, Zheng Y, Lei D, et al (2011). MDM2 309T>G polymorphism and risk of squamous cell carcinomas of head and neck: a metaanalysis. Asian Pac J Cancer Prev, 12, 1899-903.
  22. Liu YC, Hsiao HH, Yang WC, et al (2013). MDM2 promoter polymorphism and p53 codon 72 polymorphism in chronic myeloid leukemia: The association between MDM2 promoter genotype and disease susceptibility, age of onset, and blastfree survival in chronic phase patients receiving imatinib. Mol Carcinog, [Epub ahead of print].
  23. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  24. Mullighan CG (2010). Genetic variation and the risk of acute lymphoblastic leukemia. Leuk Res, 34, 1269-70. https://doi.org/10.1016/j.leukres.2010.05.013
  25. Peng Q, Mo C, Qin A, et al (2013). MDM2 SNP309 polymorphism contributes to endometrial cancer susceptibility: evidence from a meta-analysis. J Exp Clin Cancer Res, 32, 85. https://doi.org/10.1186/1756-9966-32-85
  26. Phang BH, Linn YC, Li H, Sabapathy K (2008). MDM2 SNP309 G allele decreases risk but does not affect onset age or survival of Chinese leukaemia patients. Eur J Cancer, 44, 760-6. https://doi.org/10.1016/j.ejca.2008.02.007
  27. Phillips CL, Gerbing R, Alonzo T, et al (2010). MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer, 55, 248-53. https://doi.org/10.1002/pbc.22519
  28. Picksley SM, Lane DP (1993). The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53? Bioessays, 15, 689-90. https://doi.org/10.1002/bies.950151008
  29. Poyurovsky MV, Katz C, Laptenko O, et al (2010). The C terminus of p53 binds the N-terminal domain of MDM2. Nat Struct Mol Biol, 17, 982-9. https://doi.org/10.1038/nsmb.1872
  30. Qin X, Peng Q, Tang W, et al (2013). An updated meta-analysis on the association of MDM2 SNP309 polymorphism with colorectal cancer risk. PLoS One, 8, e76031. https://doi.org/10.1371/journal.pone.0076031
  31. Ross JA (2008). Environmental and genetic susceptibility to MLLdefined infant leukemia. J Natl Cancer Inst Monogr, 39, 83-6.
  32. Tang J, Shen L, Song S, An Z, Zhang C (2014). Polymorphisms in the MDM2 gene and risk of malignant bone tumors: a metaanalysis. Tumour Biol, 35, 779-84. https://doi.org/10.1007/s13277-013-1106-3
  33. Vardiman JW, Thiele J, Arber DA, et al (2009). The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood, 114, 937-51. https://doi.org/10.1182/blood-2009-03-209262
  34. Wang J, Yang YG, Zhou M, et al (2013). Meta-analysis of randomised clinical trials comparing idarubicin + cytarabine with daunorubicin + cytarabine as the induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia. PLoS One, 8, e60699. https://doi.org/10.1371/journal.pone.0060699
  35. Wang L, Liu Z, Jing P, et al (2014). Effects of murine double minute 2 polymorphisms on the risk and survival of osteosarcoma: a systemic review and meta-analysis. Tumour Biol, 35, 1649-52. https://doi.org/10.1007/s13277-013-1227-8
  36. Xiong X, Wang M, Wang L, et al (2009). Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia. Leuk Res, 33, 1454-8. https://doi.org/10.1016/j.leukres.2009.04.007
  37. Yalcin A, Serin MS, Emekdas G, et al (2009). Promoter methylation of P15 (INK4B) gene is possibly associated with parvovirus B19 infection in adult acute leukemias. Int J Lab Hematol, 31, 407-19. https://doi.org/10.1111/j.1751-553X.2008.01052.x
  38. Yan Y, Liang H, Li T, et al (2014). Association of XRCC3 Thr241Met polymorphism and leukemia risk: evidence from a meta-analysis. Leuk Lymphoma, 55, 2130-4. https://doi.org/10.3109/10428194.2013.853303
  39. Yan Y, Liang H, Xie L, et al (2014). Association of MDR1 G2677T polymorphism and leukemia risk: evidence from a metaanalysis. Tumour Biol, 35, 2191-7. https://doi.org/10.1007/s13277-013-1291-0
  40. Zenz T, Habe S, Benner A, et al (2008). The MDM2 -309 T/G promoter single nucleotide polymorphism does not alter disease characteristics in chronic lymphocytic leukemia. Haematologica, 93, 1111-3. https://doi.org/10.3324/haematol.12738

Cited by

  1. MDM2 and TP53 Polymorphisms as Predictive Markers for Head and Neck Cancer in Northeast Indian Population: Effect of Gene-Gene and Gene-Environment Interactions vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5767
  2. Role of the MDM2 Promoter Polymorphism (-309T>G) in Acute Myeloid Leukemia Development vol.16, pp.7, 2015, https://doi.org/10.7314/APJCP.2015.16.7.2707